Two libraries of substituted benzimidazoles were designed using a 'scaffold-hopping' approach based on reported MDM2-p53 inhibitors. Substituents were chosen following library enumeration and docking into an MDM2 X-ray structure. Benzimidazole libraries were prepared using an efficient solution-phase approach, and screened for inhibition of the MDM2-p53 and MDMX-p53 protein-protein interactions. Key examples showed inhibitory activity against both targets.
Searching for dual inhibitors of the MDM2-p53 and MDMXp53 protein-protein interaction by a scaffold-hopping approach Andrey Zaytsev, 1 Barry Dodd, 1 Matteo Magnani, 3 Chiara Ghiron, 3 Bernard T. Golding, 1 Roger J. Griffin, 1 Junfeng Liu, 2 Xiaohong Lu, 2 Iolanda Micco, 3 David R. Newell, 2 Alessandro Padova, 3 Graeme
Robertson, 3 John Lunec, 2 The X-ray crystal structure of MDM2 bound to a p53-derived peptide reveals the -helical peptide bound into a deep groove on the surface of the protein, and key interactions are formed with three hydrophobic residues of p53 ( The p53 transactivation loop binds in a cleft on the surface of MDMX similar to that identified for MDM2 but with a closed conformation for Tyr99. (27, 28) . Steric hindrance of Met53 in the Leu23 pocket for MDMX may be responsible for the lack of potency against MDMX for MDM2-p53 inhibitors such as the In this paper, we describe the application of a scaffold-hopping approach to design new inhibitor chemotypes for MDM2 and MDMX (35, 36) based on heterocycle replacement, and derived from two MDM2-p53 inhibitors with significantly different core structures. In particular, starting from cis-imidazoline
(1), (18) and a class of oxindoles (7), (37, 38) benzimidazole derivatives were designed and evaluated through docking studies. The benzimidazole heterocycle was chosen as a 'privileged structure' in medicinal chemistry that is readily synthetically accessible. (39) The synthesis of small libraries yielded mixed MDM2-p53 and MDMX-p53 inhibitors with promising potency.
<structure 7>
MATERIALS AND METHODS

MDM2-p53 ELISA assay.
Compounds were assayed for MDM2-p53 inhibitory activity using ELISA assays in a 96-well format using the published method. (40) MDMX-p53 ELISA assay. MDMX-p53 inhibitory activity was determined using an analogous method incorporating a pCMV-XL5-MDMX cDNA construct (OriGene Technologies) for the in vitro coupled T7 transcription and rabbit reticulocyte lysate translation of MDMX, and a rabbit anti-MDMX antigen affinitypurified polyclonal antibody (Bethyl Laboratories Inc, via UK supplier Cambridge Bioscience, UK, Cat No.
A300-287 A).(41)
Docking experiments. Docking calculations were performed with the GOLD software. (42) Ligands were docked within the p53 binding site of MDM2, using the crystal structure of human MDM2 in complex with the small molecule inhibitor Nutlin-2 (PDB code: 1RV1). (18) A single protein chain was selected from the unit cell. The binding site was defined by hydrophobic fitting points calculated on the target for a 8Å radius around the co-crystallized ligand. GoldScore was used as a fitness function, while default genetic algorithm parameter settings were applied. 30 poses were generated for each ligand, early termination being allowed when the top 10 solutions were within 1.5Å R.M.S.D.
Chemical Synthesis.
General Procedure A -Synthesis of compounds (14).
A mixture of the appropriate aldehyde (1.2 eq.), sodium dithionite (86% purity; 1.98 g, 9.78 mmol, 3 eq.)
and 13 (1.16 g, 3.26 mmol, 1.0 eq.) in methanol (12 mL) and water (3 mL) was heated in a microwave reactor for 10 minutes at 100 o C. The sample was diluted with ethyl acetate (20 mL) and washed with water (20 mL) and brine (20 mL) . The organic layer was dried (MgSO4), and evaporated. Chromatography (silica; ethyl acetate, petrol) gave compound 14.
General Procedure B. Compound 14 was dissolved in DCM (2 mL) and TFA (3 mL) and the mixture stirred at rt for 1 hour, then evaporated. The residue was diluted with DCM (20 mL) and neutralised with sodium carbonate (sat.; 20 mL). The organic layer was dried (MgSO4) to give 15 which was used without further purification.
General procedure C.
Either an aliquot of a solution of 15 in dry DCM (1 mL, 0.049 M), or weighed 15 in dry DCM (1 mL) was treated with the named isocyanate (1.5 eq.). The mixture was quenched with NH2-silica and filtered through a plug of NH2-silica. Evaporation gave 8 without further purification. 
(S)-Ethyl 3-(3-(5-chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl
N-(4-Acetylphenyl)-4-(6-chloro-1-(4-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamide
9{4,2}
General Procedure G: 21{4} (0.097 g, 0.27 mmol), 4-acetylphenylisocyanate (0.074 g, 0.46 mmol).
Chromatography (50% EtOAc, petrol), 9{4,2} 55 %; HPLC purity (as area %) > 96; 
RESULTS
Design
The search for MDM2-p53 inhibitors has revealed several classes of small molecules able to bind MDM2 at the p53 binding site and restore p53 activity. (21) Reflecting the hydrophobic nature of the MDM2-p53
interaction, all of these compounds are characterized by a central scaffold that directs hydrophobic substituents towards the three MDM2 sub-pockets, thus mimicking the key amino acid side-chains of p53.
In an attempt to identify novel chemotypes acting as an anchor point for hydrophobic substituents, our attention was focused on compounds 1 and 7, taken as representative of two potent and structurally different classes of MDM2 inhibitors. The scaffold-hopping approach initially matched the two nitrogens of the Nutlin imidazoline ring 1 with the two nitrogens in the benzimidazole scaffold (Figure 2, red) . Overlay of the Nutlin chlorophenyl rings with the benzimidazole gave two possible orientations of the chloro group in the scaffold (8 and 9). Positions 1 and 2 of the benzimidazole ring were used to append the hydrophobic piperidinyl amide substituents judged to be necessary for activity, resulting in two different substitution patterns, represented by general structures 8 and 9 ( Figure 2 ).
<figure 2>
Docking experiments showed two separate binding modes for the enantiomers of 8{1,6}. In the case of the (R)-enantiomer the chlorobenzimidazole occupies the Phe19 pocket and the aryl urea fills the Leu26 pocket, whereas for the (S)-enantiomer the positions are reversed (Figures 3a and 3b , respectively). The docked pose for 9{1,6} shows the arylurea occupying the Leu26 pocket and the benzyl group positioned within the Phe19 pocket ( Figure 3c ). Interestingly, the Trp23 subpocket is unoccupied for all of the binding modes generated.
This pocket is known to be important from the published X-ray structures of small-molecule MDM2-p53
inhibitors. The other subpockets (Phe19 and Leu26) were occupied by the hydrophobic moieties of the ligands, thus rendering both libraries 8 and 9 worthy of exploration. For the alternative benzimidazoles 8, the (S)-enantiomers appeared to be more promising than (R)-enantiomers and therefore were prioritized for synthesis.
<figure 3a,b,c>
Synthesis
The rapid synthesis of benzimidazole libraries has been described recently using a number of approaches, including solid-phase synthesis, (43, 44) and solution-phase methods. (45) (46) (47) (48) In this case, the required N The synthesis of benzimidazoles 8 bearing substituted aryl groups required the use of suitably substituted arylacetaldehydes (10) . These were prepared from the respective benzaldehydes using a Wittig reaction giving the methyl enol ethers (11) , which were subjected to acidic hydrolysis (Scheme 1). The SNAr reaction of (S)-12 and 4-chloro-1-fluoro-2-nitrobenzene gave nitroaniline (13) 
General Methods
Reagents were purchased from fine chemicals vendors, and used as received unless otherwise stated. Solvents were (10-90%). Accurate masses were measured using a Finnigan MAR 95 XP or a Finnigan MAR 900 XLT at the EPSRC National Mass Spectrometry Service Centre (Chemistry Department, University of Wales, Swansea, Wales, SA2 8PP).
tert-Butyl 3-((4-chloro-2-nitrophenyl)amino)piperidine-1-carboxylate (13)
1,1-Dimethylethyl-3-aminopiperidine-1-carboxylate (1.29 g, 6.44 mmol) was added to a suspension of Na2CO3 (0.819 g, 7.73 mmol) and 4-chloro-1-fluoro-2-nitrobenzene (1.13 g, 6.44 mmol) in dry DMF (20 mL), and stirred at 70 o C for 2.5 hours. The mixture was diluted with water (200 mL) and extracted with ethyl acetate (3 x 70 mL). The combined organic layers were washed with water (2 x 50 mL), brine (50 mL), and dried (MgSO4), and evaporated.
Chromatography (silica; 0-20% ethyl acetate, petrol) gave 13 as a bright orange oil (1.80 g, 79% 
General Procedure A -Synthesis of compounds (14).
A mixture of the appropriate aldehyde (1.2 eq.), sodium dithionite (86% purity; 1.98 g, 9.78 mmol, 3 eq.) and 13
(1.16 g, 3.26 mmol, 1.0 eq.) in methanol (12 mL) and water (3 mL) was heated in a microwave reactor for 10 minutes at 100 o C. The sample was diluted with ethyl acetate (20 mL) and washed with water (20 mL) and brine (20 mL). The organic layer was dried (MgSO4), and evaporated. Chromatography (silica; ethyl acetate, petrol) gave compound 14.
(S)-tert-Butyl 3-(2-benzyl-5-chloro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxylate 14{1}.
General 
(S)-3-(5-Chloro-2-benzyl-1H-benzo[d]imidazol-1-yl)-N-cyclohexylpiperidine-1-carboxamide 8{1,10}.
General procedure C: 15{1} (1 mL, 49 µmol) and cyclohexyl isocyanate (11 µl, 76 µmol 
(S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-nitrophenyl)piperidine-1-carboxamide 8{2,1}.
(S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-acetylphenyl)piperidine-1-carboxamide 8{2,2}.
(S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-(3,4,5-trimethoxyphenyl
(S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethoxy
(S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethylphenyl)piperidine-1-carboxamide 8{2,5}.
General procedure C: 15{2} (1 mL, 49 µmol) and 4-(trifluoromethyl)phenyl isocyanate (11 µl, 78 µmol 
(S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-cyclohexylpiperidine-1-carboxamide 8{2,10}.
General procedure C: 15{2} (1 mL, 49 µmol) and cyclohexyl isocyanate (9 µl, 76 µmol -2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-nitrophenyl)piperidine-1-carboxamide 8{3,1} . -2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-fluorophenyl) -2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethoxyphenyl) Ethyl 4-(3-(5-chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamido) Phenylmethanesulfonyl chloride (12 mg, 60.9 µmol, 1.1 eq) was added to a solution of 15 (18 mg, 55.4 µmol, 1eq) and triethylamine (11.6 µl, 83.1 µmol, 1.5 eq) in DCM (1mL). The mixture was stirred at RT for 1h, then quenched with water (3mL 
(S)-3-(5-Chloro
General procedure C: 15{3}
(1 mL, 49.3 µmol) and 4-nitrophenyl isocyanate (12 mg, 76 µmol.5(q, J 256.6); 120.5; 121.4; 121.6; 122.8; 127.8; 129.9; 132.1; 137.4; 137.4; 143.8; 144.7; 154.1; 154.7; F NMR (470.7 MHz, CDCl3) -58.1.
(S)-3-(5-Chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethylphenyl)piperidine-1-carboxamide 8{3,5}
(S)-
General Procedure D:
A mixture of 4-chloro-2-fluoronitrobenzene (1.0g, 5.7 mmol), the required benzylamine (5 eq), potassium carbonate 
4-(1-Benzyl-6-chloro-1H-benzoimidazole-2-yl)piperidine-1-carboxylic acid tert-butyl ester 20{1}
General Procedure E: 19{1} (0.32g, 1.22mmol), sodium dithionite (0.64g, 3.66 mmol), 18 (0.29g, 1.34mmol .
General Procedure F: Boc deprotection
A mixture of 20 (0.40 g, 0.94 mmol ), TFA (0.6 mL) and DCM (2 mL) was stirred at rt for 4.5 h, then concentrated and diluted with methanol (4 mL). K2CO3 (0.2 g) was added and the suspension was stirred at rt, then filtered, and concentrated. Chromatography (5% DCM, MeOH) gave 21. Intermediates 21{2},21{3}, 21{4} were used directly in the subsequent step without purification.
1-Benzyl-6-chloro-2-(piperidin-4-yl)-1H-benzo[d]imidazole 21{1}
A mixture of 20{1} (0.40 g, 0.94 mmol ), TFA (0.6 mL) and DCM (2 mL) was stirred at rt for 4.5 h, then concentrated and diluted with methanol (4 mL). K2CO3 (200mg) was added and the suspension was stirred at rt, then filtered, and concentrated. Chromatography (5% DCM, MeOH) gave 21{1} 72%; HPLC purity (as area %) > 98; 
